250 related articles for article (PubMed ID: 36084766)
41. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
42. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
Ou Z; Chen C; Chen A; Yang Y; Zhou W
Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
[TBL] [Abstract][Full Text] [Related]
43. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
[TBL] [Abstract][Full Text] [Related]
44. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study.
Pagan AD; David E; Ungar B; Ghalili S; He H; Guttman-Yassky E
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2378-2385. PubMed ID: 35753667
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
de Wijs LEM; Bosma AL; Erler NS; Hollestein LM; Gerbens LAA; Middelkamp-Hup MA; Kunkeler ACM; Nijsten TEC; Spuls PI; Hijnen DJ
Br J Dermatol; 2020 Feb; 182(2):418-426. PubMed ID: 31145810
[TBL] [Abstract][Full Text] [Related]
46. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
[TBL] [Abstract][Full Text] [Related]
47. Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis.
Silverberg JI; Rubini NPM; Pires MC; Rossi AB; Zhang A; Chen Z; Levit NA; Chao J; Shumel B; Bégo-Le Bagousse G
J Allergy Clin Immunol Pract; 2022 May; 10(5):1279-1285.e1. PubMed ID: 35032695
[TBL] [Abstract][Full Text] [Related]
48. [EFFECTS OF DUPILUMAB ON PERENNIAL ALLERGIC RHINITIS IN ATOPIC DERMATITIS PATIENTS].
Yamamoto M; Okuno M; Sasaki T; Fujimoto R; Kataoka Y; Kawashima K
Arerugi; 2020; 69(10):979-988. PubMed ID: 33310981
[TBL] [Abstract][Full Text] [Related]
49. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
[TBL] [Abstract][Full Text] [Related]
50. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab.
Mizuno M; Horiguchi G; Teramukai S; Ichiyama S; Ito M; Hoashi T; Kanda N; Saeki H
Australas J Dermatol; 2021 Nov; 62(4):e504-e509. PubMed ID: 34523731
[TBL] [Abstract][Full Text] [Related]
51. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
[TBL] [Abstract][Full Text] [Related]
52. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis.
Mortz CG; Lauritsen JM; Bindslev-Jensen C; Andersen KE
Br J Dermatol; 2001 Mar; 144(3):523-32. PubMed ID: 11260009
[TBL] [Abstract][Full Text] [Related]
54. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
55. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials.
Silverberg JI; Simpson EL; Guttman-Yassky E; Cork MJ; de Bruin-Weller M; Yosipovitch G; Eckert L; Chen Z; Ardeleanu M; Shumel B; Hultsch T; Rossi AB; Hamilton JD; Orengo JM; Ruddy M; Graham NMH; Pirozzi G; Gadkari A
Dermatitis; 2021 Oct; 32(1S):S81-S91. PubMed ID: 33165005
[TBL] [Abstract][Full Text] [Related]
56. Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis.
Koskeridis F; Evangelou E; Ntzani EE; Kostikas K; Tsabouri S
J Cutan Med Surg; 2022; 26(6):613-621. PubMed ID: 36214355
[TBL] [Abstract][Full Text] [Related]
57. Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.
Tánczosová M; Kojanová M; Arenbergerová M; Arenberger P; Doležal T; Štrosová D; Fialová J; Gkalpakiotis S
Cent Eur J Public Health; 2022 Mar; 30(1):46-50. PubMed ID: 35421298
[TBL] [Abstract][Full Text] [Related]
58. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.
Silverberg JI; Boguniewicz M; Hanifin J; Papp KA; Zhang H; Rossi AB; Levit NA
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2731-2746. PubMed ID: 36269503
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single-center retrospective study.
Li Y; Lu J; Chen R; Wang Y; Ding Y; Xu S; Zou Y; Yi X; Shi Y
Dermatol Ther; 2022 May; 35(5):e15385. PubMed ID: 35174593
[TBL] [Abstract][Full Text] [Related]
60. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
